Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ ...

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

Technical indicators have turned bullish for the three stocks.

Dexcom Inc. (US2521311074) stock is trading near USD 89.71 on September 4, 2026, with a market cap of USD 33.85 billion. The ...

DexCom Inc., a maker of monitoring devices for diabetes patients, cut its full-year sales outlook on Thursday — a move that surprised some analysts and investors and sent its stock tumbling after ...

DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.

Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will ...